Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 26 tags : Cancer save search
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-26 (Crawled : 14:00) - biospace.com/
EPIX | $6.67 -5.66% -6.0% 36K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
epi-7386 candidate results cancer study prostate cancer phase 1
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Published: 2022-10-26 (Crawled : 14:00) - globenewswire.com
GTHX | News | $4.16 -2.8% -2.88% 690K
|
Health Technology
|
| O: -0.62%
H: 5.64%
C: -0.81%
lung trilaciclib therapeutics cancer study initiated
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
ANIX 4 | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: 0.76%
H: 10.38%
C: 9.62%
vaccine breast trial cancer phase 2b
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
BDTX A | $5.295 -7.11% -7.65% 1.9M
|
Health Technology
|
| O: 0.6%
H: 11.98%
C: 4.19%
bdtx-1535 preclinical symposium therapeutics molecular cancer
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
QSAM | $7.4 -31.58% 3.7K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -7.72%
cyclosam treatment bone trial cancer study
HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
HTGM | $0.48 -20.0% -26.08% 0
|
Health Technology
|
| O: 3.93%
H: 2.95%
C: -4.61%
cancer
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
Published: 2022-10-26 (Crawled : 09:00) - globenewswire.com
MRUS | $40.41 -1.56% -1.58% 240K
|
Health Technology
|
| O: -1.06%
H: 3.59%
C: -8.84%
mcla-129 symposium therapeutics molecular cancer
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.